Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course

Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course

Bibliographic Details
Main Authors:	Anam Tariq, Ayobami Akenroye, Antoine Azar, Philip Seo, Duvuru Geetha
Format:	Article
Language:	English
Published:	AVES 2022-04-01
Series:	European Journal of Rheumatology
Online Access:	https://www.eurjrheumatol.org/en/rituximab-associated-hypogammaglobulinemia-in-anca-associated-vasculitis-incidence-and-time-course-133446

Similar Items

Immunotherapy for ANCA-associated vasculitis during the COVID-19 pandemic
by: Eric J. Gapud, et al.
Published: (2020-08-01)

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
by: Jones, R, et al.
Published: (2010)

Is rituximab effective for induction of remission in ANCA-associated vasculitis?
by: Carmen Rain, et al.
Published: (2015-08-01)

Levamisole adulterated cocaine associated ANCA vasculitis: review of literature and update on pathogenesis
by: Qiuyu Jin, et al.
Published: (2018-11-01)

Immune checkpoint inhibitors as potential triggers for ANCA vasculitis
by: Duvuru Geetha, et al.
Published: (2022-11-01)

Outcomes of COVID-19 in patients with ANCA-associated vasculitis receiving avacopan
by: John L Niles, et al.
Published: (2023-07-01)

The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review
by: Mohammad Amin Habibi, et al.
Published: (2022-12-01)

Randomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS
by: Jones, R, et al.
Published: (2009)

Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives
by: Elena Treppo, et al.
Published: (2021-08-01)

Is Rituximab-Associated Hypogammaglobulinemia Always Linked to B-Cell Depletion?
by: Anthie Damianaki, et al.
Published: (2022-02-01)

ANCA Associated Vasculitis Treated with Ultra-low Dose Rituximab: A Case Report
by: WU Haiting, et al.
Published: (2023-11-01)

Hypophysitis Secondary to Small Vessel ANCA Vasculitis Treated With Rituximab
by: Nankee K. Kumar, AB, et al.
Published: (2024-03-01)

Immunopathogenesis of ANCA-Associated Vasculitis
by: Andreas Kronbichler, et al.
Published: (2020-10-01)

ANCA-Associated Vasculitis: An Update
by: Salem Almaani, et al.
Published: (2021-04-01)

Updates in ANCA-associated vasculitis
by: Carolyn Ross, et al.
Published: (2022-07-01)

Ten-year experience with rituximab for induction and maintenance therapy in patients with ANCA-associated systemic vasculitis
by: T. V. Beketova, et al.
Published: (2020-03-01)

Rituximab in ANCA-associated vasculitis presenting with severe acute kidney injury; a case report
by: Macaulay Onuigbo, et al.
Published: (2019-01-01)

ANCA‐associated vasculitis with scleritis, corneal melt, and perforation rescued by rituximab: Case report and literature review
by: Toshihiko Matsuo, et al.
Published: (2023-06-01)

Explaining fatigue in ANCA-associated vasculitis
by: Basu, N, et al.
Published: (2013)

Explaining fatigue in ANCA-associated vasculitis.
by: Basu, N, et al.
Published: (2013)

Outcome measures in ANCA-associated vasculitis.
by: Suppiah, R, et al.
Published: (2010)

Diagnosis and management of ANCA associated vasculitis.
by: Berden, A, et al.
Published: (2012)

Damage assessment in ANCA-associated vasculitis.
by: Bhamra, K, et al.
Published: (2012)

Cutaneous manifestations of ANCA-associated vasculitis
by: Chiesafuxench, Z, et al.
Published: (2016)

Cardiovascular outcomes in ANCA associated vasculitis
by: Mukhtyar, C, et al.
Published: (2008)

Granulomatous Inflammation in ANCA-Associated Vasculitis
by: Antje Müller, et al.
Published: (2021-06-01)

The involvement of NETs in ANCA-associated vasculitis
by: Satoka Shiratori-Aso, et al.
Published: (2023-09-01)

Serum B cell activating factor (BAFF) as a biomarker for induction of remission with rituximab in ANCA-associated vasculitis
by: Kazuyuki Tsuboi, et al.
Published: (2022-10-01)

Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab)
by: T. V. Beketova, et al.
Published: (2020-09-01)

COVID-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab)
by: T. V. Beketova, et al.
Published: (2018-06-01)

Late-onset neutropenia induced by anti-B cell therapy with rituximab in patients with ANCA-associated systemic vasculitis
by: T. V. Beketova, et al.
Published: (2022-06-01)

Rituximab and hypogammaglobulinemia in the setting of ABO-incompatible kidney transplantation
by: Hamza Naciri Bennani, et al.
Published: (2018-07-01)

Research advances on the impact of environmental risk factors on the incidence of ANCA-associated vasculitis
by: Min-min Xiao, et al.
Published: (2023-10-01)

Markers for work disability in ANCA-associated vasculitis
by: Basu, N, et al.
Published: (2013)

Maintenance of clinical remission in ANCA-associated vasculitis.
by: Luqmani, R
Published: (2013)

Predictors of renal involvement in ANCA associated vasculitis
by: Kronbichler, A, et al.
Published: (2018)

Long-term survival of ANCA-associated vasculitis
by: Flossmann, O, et al.
Published: (2009)

B Lineage Cells in ANCA-Associated Vasculitis
by: Ana Merino-Vico, et al.
Published: (2021-12-01)

Renal thrombotic microangiopathy in an ANCA-associated vasculitis
by: Ana Teresa Domingos, et al.
Published: (2019-10-01)

Treatment of renal manifestations of ANCA-associated vasculitis
by: Kresimir Galesic, et al.
Published: (2013-01-01)